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Abstract We have identified, using site-directed mutagenesis, a
proline located at position 13 of BaxK (Bax) as crucial for the
maintenance of its cytosolic conformation. The substitution of
this proline by a valine results in a strong binding of Bax to
mitochondria and to conformational changes monitored by a
decreased sensitivity of Bax to mild proteolysis and the
enhancement of its oligomerization state. Deletion of the C-
terminus of Bax does not modify its intracellular localization. On
the other hand, the pro-apoptotic activity of Bax is enhanced by a
deletion of the C-terminus in the absence of the N-terminus but is
decreased in its presence. These results suggest that both
extremities functionally interact to control the activity but not
the subcellular localization of Bax. ß 2002 Published by Else-
vier Science B.V. on behalf of the Federation of European Bio-
chemical Societies.
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1. Introduction
The control of apoptosis, a form of programmed cell death,
is an essential feature for the maintenance of cellular homeo-
stasis in healthy as well as in pathological tissue [1^3]. Pro-
teins which belong to the Bcl-2 (B-cell lymphoma) family can
either stimulate (Bax, Bak, Bad, Bid, etc.) or inhibit apoptosis
(Bcl-2, Bcl-XL, Mcl-1, etc.) [4^6]. In viable cells, these pro-
teins exhibit di¡erent subcellular localizations: Bcl-2 and Bak
are mainly mitochondrial while BH3 only pro-apoptotic pro-
teins such as Bad and Bid are cytosolic [4^6]. On the other
hand, BaxK (Bax) and Bcl-XL are both cytosolic and mem-
brane-bound in non-apoptotic cells [7^11]. Upon the induc-
tion of apoptosis, Bax, Bid and Bad are targeted to the mi-
tochondria and participate in the activation of the execution
phase of apoptosis by triggering the release of mitochondrial
apoptogenic proteins such as the cytochrome c [4^6]. The
addressing and/or the insertion of these proteins in the mito-
chondrion is one of the rate-limiting steps in the activation of
the mitochondrial pathway of cell death [7]. The anti-apopto-
tic proteins Bcl-2 and Bcl-XL are targeted and inserted into
the mitochondrial outer membrane by their hydrophobic C-
terminal extremities [12^14]. Since Bax displays a hydrophobic
C-terminus, it has been proposed that this segment anchors
this protein to the mitochondrial outer membrane [15]. How-
ever, the role of the COOH-terminus of human Bax (CT) in
the membrane integration process and in its pro-apoptotic
function is unclear as deletions, mutations or substitutions
within this sequence have given contradictory results both in
mammals and in Saccharomyces cerevisiae [10,16^21]. Goping
et al. [17] showed that the NH2-terminus of human Bax (NT)
was involved in the regulation of Bax targeting to the mito-
chondria and thus called this sequence ART for apoptotic
regulation of targeting. The deletion of ART caused a rapid
association of Bax with the mitochondria and induction of cell
death [17]. It has also be suggested that the cytosolic confor-
mation of Bax is secured by the interaction of the hydropho-
bic CT with the NT [17,18,20]. In this work, we have exam-
ined by site-directed mutagenesis the amino acids involved in
the ART function and the relationship between the NT and
the CT of Bax.
2. Materials and methods
2.1. Reagents
Unless speci¢ed, all reagents used in this study were from Sigma
(St. Louis, MO, USA). Monoclonal Bax antibody (clone 4F11) was
from Immunotech (France) and was used at a concentration of 1 Wg/
ml in confocal microscopy experiments. The mitochondrion-selective
probe Mitotracker Green FM was obtained from Molecular Probes
(Interchim, France) and the £uorogenic peptide Ac-DEVD-AMC
from Bachem (France).
2.2. Plasmids and cell transfections
N-terminal mutants of Bax were obtained by site-directed muta-
genesis using the PCR-based Gateway1 method and were subcloned
in pDEST plasmids according to the manufacturer’s instructions (In-
vitrogen, Parsley, UK). Primers used for site-directed mutagenesis
were BaxK (Bax) (5P-GGGGACAAGTTTGTACAAAAAAGCAGGC-
TTCATGGACGGGGAGCAGCCCAGAGGCGGG-3P), BaxvART
(5P-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGAAGA-
CAGGGGCCCTTTTGCTTCAGTTCAT-3P), BaxvS4L (5P- GGGG-
ACAAGTTTGTACAAAAAAGCAGGCTTCATGGACGGGTTAG-
GGGAGCAGCCCAGAGGCGGG-3P), BaxS15L (5P-GGGGACA-
AGTTTGTACAAAAAAGCAGGCTTCATGGACGGGTCCGGG-
GAGCAGCCCAGAGGCGGGCCCACCCTCTCTGAAACAG-3P),
BaxP8V (5P- GGGGACAAGTTTGTACAAAAAAGCAGGCTTCAT-
GGACGGGTCCGGGGAGCAGCTCAGAGGCGGG-3P), BaxP13-
V (5P-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGGAC-
GGGTCCGGGGAGCAGCCCAGAGGCGGCGGGGCCACCAG-
C-3P), BaxP8V/P13V (5P-GGGGACAAGTTTGTACAAAAAAGCA-
GGCTTCATGGACGGGTCCGGGGAGCAGCTCAGAGGCGG-
CGGGGCCACCAGC-3P), BaxP8L/R9G (5P-GGGGACAAGTTTG-
TACAAAAAAGCAGGCTTCATGGACGGGTCCGGGGAGCAG-
CTCGGAGGCGGG-3P), BaxvC (5P-GGGGACAAGTTTGTACA-
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AAAAAGCAGGCTACAAAAAAGCAGGCTATGCCACGTGGG-
CGTCCCAAAGTAGGAGAGGAG-3P) and BaxC (5P-GGGGAC-
AAGTTTGTACAAAAAAGCAGGCTTTCAGCCCATCTTCCAGA-
TGGTGAGCGAGGCGGTGAGCA-3P).
A Bax-de¢cient cell line derived from a human glioblastoma multi-
forme (BdGBM) (Cartron et al., in preparation) was transfected with
the empty vector (pDEST 12.2, Life Technologies) or Bax mutants
cloned into this vector. Plasmid DNAs (5 Wg) were introduced into
106 BdGBM cells by electroporation (GenePulser, Bio-Rad) using 200
V/cm and 250 WF; the transfected cells were selected in a medium
containing neomycin (250 Wg/ml) for 48 h. After selection, the bulk
of transfected cells was used in in vitro experiments as previously
described [10].
2.3. Acellular assay of Bax insertion
Mitochondria were prepared from normal rat liver and the cell-free
association of Bax with the mitochondria was performed as described
previously [21]. Brie£y, 35S-Met (Amersham, France) labeled proteins
were synthesized from cDNAs using the TNT coupled transcription/
translation system from Promega (France). Post-translational inser-
tion of labeled proteins into mitochondrial membranes and alkaline
treatment of mitochondrial bound proteins were performed in a stan-
dard import bu¡er as described previously [21]. Radiolabeled proteins
bound to the mitochondria were recovered in the pellet after centri-
fugation of the incubation mixture for 10 min at 4‡C at 8000Ug. 35S-
Met-Bax associated with isolated mitochondria were analyzed in an
SDS^PAGE and scanned with a phosphorimager (Molecular Dynam-
ics, France). The amount of proteins present in the gel slab was sub-
sequently quanti¢ed with IPLab gel program (Signal Analytics, Vien-
na, VA, USA).
The association of Bax with Bid was performed using puri¢ed His-
tagged full-length Bid described by Eskes et al. [22]. In mitochondrial
association experiments, radiolabeled Bax and cold His-Bid were in-
cubated together for 30 min before their addition to isolated rat liver
mitochondria and the analysis of the insertion of Bax into the mem-
branes.
2.4. Quanti¢cation of apoptosis
BdGBM cells (2U106 cells), transfected with the di¡erent bax con-
structs, were cultured in the presence or in the absence of doxorubicin
(doxo, 2 Wg/ml) for 24 h before quanti¢cation of apoptosis by mea-
surement of the LDH and DEVDase activities as previously described
[10]. Brie£y, the LDH activity was measured using a Cytotox960
assay from Promega (France) in the culture medium after the induc-
tion of apoptosis while the cells were washed several times with PBS,
plated in 96-well plates and the caspase-3 £uorogenic substrate (Ac-
DEVD-AMC), added in the presence of 0.01% Triton X-100.
2.5. Confocal analysis
For confocal analysis, the cells were incubated for 30 min with 5 Wg/
ml Mitotracker Green FM at 37‡C then ¢xed with 1:1 methanol/
acetone for 15 min at 320‡C. After saturation with 3% BSA in
PBS the cells were incubated with anti-Bax antibody 1 h at room
temperature. After extensive washing, a second anti-mouse IgG
coupled to rhodamine was added overnight at 4‡C. Images were col-
lected on a Leica TCS NT microscope with an 100U 1.3 NA Fluotar
objective (Leica, France).
2.6. Protein binding experiments
The coding regions of Bax and BaxvART were subcloned in
pDEST17 plasmid in order to add a histidine tag at the N-terminus
of the coding region. The His-tagged proteins were expressed in bac-
teria and puri¢ed according to the manufacturer’s instructions. In
vitro His protein binding assays were performed as followed: Bax,
BaxvART and BaxP8V/P13V were in vitro translated and labeled
with 35(S)-methionine as described above. Equal amounts of each
labeled protein (4 fmol) were then diluted with 250 Wl of binding
bu¡er (142 mM KCl, 5 mM MgCl2, 10 mM HEPES (pH 7.4), 0.5
mM DTT, 1 mM EGTA, 0.5 mM phenylmethylsulfonyl £uoride, and
a mixture of other protease inhibitors) and incubated with an equi-
molar concentration of the His-tag-BaxvART or His-tag-Bax immo-
bilized on Ni-Sepharose at 4‡C for 2 h. The resins were then exten-
sively washed with binding bu¡er, and the His protein binding
complexes were eluted with bu¡er containing 50 mM Tris^HCl (pH
8.0), 1 mM DTT, and 250 mM imidazole before the analysis by SDS^
PAGE and £uorography.
3. Results
3.1. Association of Bax mutants with mitochondria
To explore the relative importance of the NT and the CT in
the association of Bax with mitochondrial membranes, we
have constructed mutants which lack either the NT (deletion
of amino acids 1^19) and/or the CT (deletion of amino acids
172^193) (Fig. 1A). We analyzed the association of 5 fmol
Bax or its mutants with puri¢ed rat liver mitochondria using
a cell-free assay (cf. Section 2). The ratio between 35S-Met-
labeled proteins and mitochondria was chosen as it was below
the mitochondrial saturation level for Bcl-2 [21]. As shown in
Fig. 1B, the 35S-Met-labeled Bax bound poorly to rat liver
mitochondria whereas a truncation of the NT (BaxvART)
dramatically increased the membrane association (P =
0.0004) as previously shown by Goping et al. [17]. We also
studied the in£uence of a deletion of the CT (vC) on the
acellular binding of Bax (Fig. 1B). We found that the deletion
of the hydrophobic construct had no in£uence on the binding
of Bax to the mitochondria (P = 0.688) as we have previously
reported [21] but slightly enhanced that of vARTvC
(P = 0.0451) (Fig. 1B). Alkali treatment of the mitochondrial
Fig. 1. In£uence of the NT and the CT of Bax on its association
with the mitochondria in a cell-free assay. A: Schematic representa-
tion of the ART sequence, CT and BH domains in Bax wild type
and its mutants. B: Association of Bax mutants with mitochondria.
35S-Met-labeled Bax mutants were incubated with isolated rat liver
mitochondria (50 Wg) in a standard import bu¡er as described in
Section 2. At the end of the reaction (1 h at 37‡C) the mitochondria
were recovered by centrifugation and directly analyzed on SDS^
PAGE and £uorography. Bax bound to the mitochondria (mit) or
extracted with 0.1 M Na2CO3 (pH 11.5) (alkaline treatment: AT) as
well as 25% of the initial input (total radiolabeled proteins initially
added to mitochondria) (25% or 1 fmol) were analyzed in the same
gel. Histograms show the amount of protein (fmol) present in the
mitochondrial pellet before and after alkali treatment. Data shown
are the mean þ S.D. obtained from at least four independent experi-
ments.
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bound Bax constructs indicated that only the vART con-
structs (ART and vARTvC) were integrated into the mem-
brane and/or strongly associated with an integral membrane
protein (Fig. 1B). These results suggested that the NT and not
the CT of Bax played a major role in the control of the
targeting and/or the association of Bax to the membrane in
this cell-free system.
A cell line derived from a human glioblastoma multiforme
which did not express Bax (BdGBM, Cartron et al., in prep-
aration) was transfected with the di¡erent mutants used in the
cell-free assay. The bulk of transfected cells was used in this
study to avoid bias due to the cloning procedure and also
because similar levels of expression of Bax transgenes were
found under these conditions (data not shown). Their subcel-
lular localization was determined by laser confocal microsco-
py using Mitotracker Green to identify the mitochondria.
Both Bax and BaxvC transgenes were localized in the mito-
chondrial and in the cytosolic compartments. Deletion of the
ART domain provoked a redistribution of Bax to the mito-
chondria, a tendency which was accentuated in the double
deleted construct vARTvC (data not shown). These results
were qualitatively in agreement with the data obtained in
the cell-free assay and thus underline the fundamental role
of ART in the cytosolic retention of Bax.
3.2. A proline located in the N-terminal domain of Bax is
essential for ART function
To address the question of the nature of the ART sequence
involved in the retention of Bax in the cytosol of healthy
cytosol, we engineered a series of mutations in the NT of
Bax by site-directed mutagenesis as described in Section 2.2.
As illustrated in Fig. 2A, the NT sequence of Bax contained
several Pro which could play an important role in the control
of the conformation. Indeed, the protein crystallography
structure of Bax indicated that the ¢rst 12 amino acids in
the NT were highly mobile, the second Pro being the 13th
amino acid [23]. We have analyzed the e¡ect of the substitu-
tion of these Pro as well as that of several Ser on the associ-
ation of Bax with the mitochondria in the cell-free assay. The
substitution of Ser-4 or Ser-15 by a Leu had little or no
in£uence on the binding of Bax to the mitochondria (BaxS4L
vs. Bax: P = 0.09; BaxS15L vs. Bax: P = 0.336) (Fig. 2B). On
the other hand, the substitution of Pro-13 for a Val (P13V)
enhanced signi¢cantly the association of Bax with mitochon-
dria (P = 0.003), while the substitution of the other Pro (P8)
present in the NT of Bax had no in£uence on the binding to
the mitochondria (P = 0.782) (Fig. 2B). However, the com-
bined substitution of both Pro had a more pronounced in£u-
ence on Bax binding to mitochondria than that of Pro-13
Fig. 2. Association of ART mutants with mitochondria in a cell-free assay and in vitro. A: Schematic representation of the di¡erent NT muta-
tions used in the construction of BaxART mutant expression vectors. B: Association of BaxART mutants with puri¢ed rat liver mitochondria.
The binding of BaxART mutants with isolated rat liver mitochondria was performed as described for Bax mutants in Fig. 1. Histograms show
the amount of protein (fmol) present in the mitochondrial pellet. Data shown are the mean þ S.D. obtained from at least four independent ex-
periments.
FEBS 25716 8-2-02
P.-.-F. Cartron et al./FEBS Letters 512 (2002) 95^100 97
alone (Bax vs. BaxP8V/P13V: P = 0.0017; BaxP8V/P13V vs.
BaxP13V: P = 0.013). Thus our results suggest a cooperation
between the two Pro for the maintenance of the cytosolic
conformation of human Bax. Interestingly, the sequence
equivalent to PRG (amino acids 8^10) in human Bax is
LGG in rat Bax [24], suggesting that the Pro-8 is not essential
in the cytosolic retention of Bax. Indeed, the double mutation
of the human Bax sequence for that of the rat had no in£u-
ence on Bax binding to mitochondria (human Bax ‘PRG’ vs.
rat Bax ‘LGG’: P = 0.228). Confocal analysis of Bax local-
ization in BdGBM cells revealed that the substitution of Ser
by a Leu had no e¡ect on Bax localization while the substi-
tution of one or two Pro by Val induced a mitochondrial
redistribution of Bax (data not shown). The latter results sug-
gested that the Pro located at position 13 of human Bax
played an important role in the cytosolic conformation of
human Bax and that the mutation of this amino acid caused
the insertion of Bax into the mitochondria and/or its binding
to an integral membrane protein.
3.3. In£uence of the NT on Bax conformation and interaction
with Bid
We and others have reported that a change in the Bax
conformation could be monitored by its sensitivity toward
mild proteolysis [18,21,25]. Thus, the in£uence of mutations
in NT on its conformation was studied using sensitivity to-
ward trypsin as described previously [21]. As shown in Fig.
3A, Bax was highly sensitive to mild proteolysis by trypsin
while the P8V/P13V mutant showed some resistance toward
trypsin. Similarly the vART construct was more resistant to
proteolysis. Similar results were obtained with proteinase K
(data not shown). On the other hand, deletion of the vC or
the substitution of Ser-15 by a Leu had no e¡ect on protease
sensitivity. These results suggested that the speci¢c modi¢ca-
tions of the NT which enhanced Bax binding to mitochondria
also altered its overall conformation.
Bax oligomerization has also been shown to be associated
with its change in conformation at the onset of the apoptotic
program [26,27]. His-tagged Bax and His-tagged BaxvART
puri¢ed proteins were incubated with in vitro labeled 35S-
Bax, 35S-BaxvART and 35S-BaxP8V/P13V (see Section 2.6).
As illustrated in Fig. 3B, no binding of BaxvART with Bax
was observed in this assay whereas both BaxvART and
BaxP8V/P13V bound vigorously to the His-tagged BaxvART
(P = 0.0011 and P = 0.001 respectively). On the other hand, no
speci¢c binding of 35S-Bax, 35S-BaxvART and 35S-BaxP8V/
P13V was observed with His-tagged Bax (data not shown).
The latter results suggested that the deletion or the mutation
of NT enhanced the oligomerization of Bax.
Similarly, it has been reported that Bid induced a change in
the conformation of Bax which in turn triggered its translo-
cation to the mitochondria [22,27]. We co-incubated 5 fmol
35S-Met-labeled Bax (i.e. 100 nM) with puri¢ed His-tagged
full-length Bid at a concentration range from 1 to 100 nM.
As reported earlier by Eskes et al. [22], the association of Bax
with the mitochondria was increased when equimolar concen-
trations of Bid were used (data not shown and Fig. 3C). We
C
Fig. 3. ART mutations induce a change in conformation of Bax. A:
Sensitivity of BaxART mutants to mild proteolysis. In vitro trans-
lated BaxART mutants were incubated with trypsin (1 mg/ml) for
15 min at 4‡C. At the end of the incubation the proteolysis was
stopped by the addition of 10 mg/ml soybean trypsin inhibitor and
immediately heated in denaturating bu¡er before analysis on 15%
SDS^PAGE. The data illustrated are representatives of at least three
di¡erent experiments. B: Proteins binding assay. In vitro translated
Bax, BaxvART and BaxP8V/P13V were incubated with puri¢ed
His-tagged BaxvART as described in Section 2. The percentage of
35S-labeled proteins bound to His-tagged vART was estimated after
SDS^PAGE and £uorography using the initial input (4 fmol) as
100%. Data obtained from four di¡erent experiments. C: In£uence
of Bid on the acellular association of BaxART mutants with mito-
chondria. Bax, BaxS15L, BaxP8V/P13V and BaxvART mutants
were incubated in the absence or in the presence of 100 nM full-
length Bid and bound radiolabeled proteins were recovered by cen-
trifugation and treated as described in Fig. 1 (AT alkali treatment).
Data presented are the mean þ S.D. obtained from at least three in-
dependent experiments.
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incubated the NT mutants of Bax (BaxvART, BaxS15L and
BaxP13V) with 100 nM full-length His-tagged Bid and ana-
lyzed the association of the constructs with rat liver mitochon-
dria. As illustrated in Fig. 3C, the mitochondrial association
of BaxvART and BaxvP13V was not a¡ected by a co-incu-
bation with Bid while that of Bax and BaxS15L were signi¢-
cantly enhanced (Fig. 3). We found that constructs which
associated with mitochondria in the presence of Bid such as
Bax a or BaxS15L were membrane integrated as they were
resistant to an alkaline extraction while BaxP13V, BaxP8V/
P13V and BaxART membrane integration was not a¡ected by
the presence of Bid (Fig. 3C). To control the speci¢city of the
Bid/Bax interaction, Bax was preincubated with puri¢ed His-
tagged irrelevant proteins and in this case no increase in the
binding of Bax was observed (data not shown). Thus, the Pro-
13 substitution could bypass the Bid ‘assistence’ to bind mi-
tochondria as reported for the vART mutant [28].
3.4. E¡ect of the NT mutations on Bax pro-apoptotic activity
We have analyzed the sensitivity to apoptosis of BdGBM
cells transfected with the Bax mutants. It should be noted that
the expression of the transgenes did not induce apoptosis in
the absence of doxo, probably because of the extreme resis-
tance of these cells to apoptosis (Cartron et al., in prepara-
tion). Apoptosis was induced with 2 Wg/ml doxo and cell
death was assayed by measuring the release of the cytosolic
LDH into culture media and the cellular DEVDase activity as
previously described [10]. The expression of bax transgene
enhanced the sensitivity of BdGBM cells to doxo (Fig. 4).
Quite interestingly, the deletion of the CT appeared to slightly
inhibit the pro-apoptotic activity of Bax (P = 0.004) but en-
hanced that of BaxvART (P = 0.001) (Fig. 4). As shown in
Fig. 4, the DEVDase activity as well as the release of LDH
were signi¢cantly increased in cells transfected with the Bax
constructs mutated in the ART region which possessed a high-
er a⁄nity for the mitochondria (e.g. vART, vARTvC,
BAXP13V and BAXP8V/P13V). On the other hand, no di¡er-
ences in the induction of apoptosis were observed between
cells transfected with Bax and those transfected by the ART
mutants S4L and S15L (Fig. 4).
4. Discussion
In the present work, we have investigated the nature of the
amino acids involved in the cytosolic retention and/or mito-
chondrial sorting of Bax. We ¢rst addressed the question of
the nature of the signal involved in Bax targeting to the mi-
tochondria. By analogy with Bcl-2, the hydrophobic CT of
Bax has been proposed to be the membrane addressing/inser-
tion sequence. However, we and others have not observed a
di¡erence in the apoptotic subcellular localization of CT de-
leted Bax (BaxvC) [16,19,21] while others found that this de-
letion impaired its targeting to mitochondria [8]. The com-
plexity of the signal contained in the CT was emphasized by
Nechustan et al. [20] who found that this sequence was not a
membrane addressing signal unless a strategic Ser located at
position 184 of human Bax was deleted or mutated into an
Ala residue. In addition, these authors showed that the nature
of the amino acid substituted could drastically a¡ect the intra-
cellular localization of the Bax mutants, as substitutions for a
charged amino acid blocked the binding to mitochondria and
even seemed to protect cells from cell death [20].
In this work, we show that the association of Bax con-
structs is not a¡ected by the deletion of CT suggesting that
this sequence is not a key determinant for Bax subcellular
localization both in a cell-free system or in transfection experi-
ments using a Bax-de¢cient cell line. On the other hand, the
nature of the CT appears to a¡ect its function as a substitu-
tion by the highly homologous CT of Bcl-XL does not a¡ect
its intracellular localization but inhibits the apoptotic action
of Bax in mammals and in yeast [10]. In agreement with the
latter results, we report in this work that the deletion of the
CT increases Bax pro-apoptotic activity in the absence of
ART (Fig. 4). It is likely that this inhibition results from
the nature of the interaction of the CT with ART since the
deletion of only the CT decreased the pro-apoptotic activity
of Bax (Fig. 4). One could postulate that the removal of the
CT favors a change in the conformation of the NT, however,
insu⁄cient to alter the cytosolic conformation of Bax imposed
by the ART domain. Indeed, as noted by Nechustan et al. [20]
a deletion of the CT exposed an otherwise hidden NT epitope
recognized by the conformation-dependent monoclonal anti-
body 6A7. The recent resolution of the three-dimensional
structure of Bax shows that the CT is located in the hydro-
phobic pocket occupied by the BH3 and, therefore, it has been
proposed that it could inhibit the formation of homodimers of
Bax [23], a prerequisite for the binding of Bax to mitochon-
Fig. 4. Pro-apoptogenic activity of Bax mutants in vitro. A: Immu-
noblot analysis of the expression of bax transgenes in the BdGBM
cells. B: The cellular DEVDase activity (top) and LDH activity re-
lease into the culture medium were assayed in doxo-treated BdGBM
cells transfected with the di¡erent Bax mutants. Experiments illus-
trated are the mean þ S.D. of at least three di¡erent experiments.
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dria. Alternatively, as recently suggested [10,29], the CT could
regulate Bax activity by its interaction as a receptor binding
domain with other mitochondrial proteins.
The cytosolic/mitochondria conformational transition of
Bax seems to be controlled, at least partially, by its ¢rst 20
amino acids. Nechustan et al. [20] have shown that residues
Pro-13^Ile-19 of the K1-helix are hidden in the cytosolic form
of Bax and become accessible to antibody binding after the
membrane insertion induced during apoptosis. Our results
show that a substitution of the Pro-13 plays an essential
role in the structure of this segment prior to the binding of
Bax as a substitution of this Pro by a Val results in the dra-
matic relocalization of Bax both in a cell-free assay (Fig. 2)
and in vitro (data not shown). Mutations of other amino acids
located in the ¢rst 19 residues have little or no e¡ect on the
binding of Bax to the mitochondria (Fig. 2). The three-dimen-
sional analysis of Bax revealed that the ¢rst 12 NT amino
acids are highly £exible and thus are not likely to adopt an
ordered conformation in solution [23,24]. However, as pointed
out by Roucou and Martinou [30], the structure revealed by
Susuki et al. [23] could represent only one of the possible
folding states of Bax.
The interaction of Bax with Bid has recently been shown to
be suppressed in BaxvART [28] and we show in our work that
the ART mutant P13V also bypasses the requirement of Bid
for the mitochondrial integration of Bax (Fig. 3). NT deletion
or mutation of Pro-13 appears to induce a change in confor-
mation as judged by protease sensitivity, protein binding assay
(Fig. 3) as well as the lack of interaction with Bid (Fig. 3).
Khaled et al. [25] have shown a Bax mutant in which Asp-2
and Glu-6 are exchanged for Ala undergoes a change in the
conformation viewed by an increased sensitivity to proteases.
However, in the latter case the interaction of this mutant with
the mitochondria was not documented [25]. The increase of
the interaction between Bax mutants (Fig. 3C) suggests that
the mutations of the Pro-13 or the removal of ART favor the
dimerization among bax molecules. The latter process which
is likely to occur through the BH3 domains could induce the
association of these mutants to mitochondria [5]. The corre-
lation between the property of NT mutants to dimerize, to
bind mitochondria and their ability to induce apoptosis high-
lights thus the importance of the N-terminal end in the regu-
lation of the structure/activity of Bax (Fig. 4). Recent results
have shown that cleavage of Bax by calpain results in the
generation of a very apoptogenic 18 kDa fragment [31]. It is
noteworthy that in our condition, this cleavage is observed
only at very late stages of apoptosis and after the integration
of Bax into the membrane (data not shown) ruling out that
this degradation is a prerequisite for the early activation of
bax.
In conclusion, our results suggest that a proline present in
the ART sequence is involved in the maintenance of an in-
nocuous conformation of Bax which is only released at the
onset of apoptosis by factors like BID. More importantly, the
‘dialog’ between NT and CT appears to be more critical for
the control of bax activity than for its subcellular localization.
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